Indatuximab ravtansine
Indatuximab ravtansine is a monoclonal antibody designed for the treatment of cancer. This drug was developed by ImmunoGen.
Mechanism of Action[edit | edit source]
Indatuximab ravtansine is a monoclonal antibody that targets the CD138 antigen, a protein that is overexpressed in multiple myeloma cells. The drug is linked to a cytotoxic agent, maytansinoid, which is released into the cancer cell upon binding to the CD138 antigen. This leads to cell death and reduction in tumor size.
Clinical Trials[edit | edit source]
Indatuximab ravtansine has been studied in several clinical trials for the treatment of multiple myeloma. In a phase II study, the drug showed promising results in patients with relapsed or refractory multiple myeloma.
Side Effects[edit | edit source]
Common side effects of indatuximab ravtansine include fatigue, nausea, and diarrhea. Serious side effects can include neutropenia, anemia, and thrombocytopenia.
See Also[edit | edit source]
References[edit | edit source]
Indatuximab ravtansine Resources | ||
---|---|---|
|
|
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD